Help us: Donate
Follow us on:



Eric Leire on Genflow Biosciences at EARD2020

This company intends to use SIRT6 to benefit the epigenome and downstream hallmarks.

Dr. Eric LeireDr. Eric Leire

At Ending Age-Related Diseases 2020, Dr. Eric Leire of Genflow Biosciences discussed his company, explaining what Genflow does and how it is funded. The company is intervening directly in the biology of aging, affecting SIRT6, which, like other sirtuins, is a known regulator of aging. The company intends to develop its SIRT6 plasmid as an epigenomic therapy that will affect downstream hallmarks of aging, potentially providing a broad-based solution to multiple age-related diseases.

Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension: YouTube Facebook Twitter Instagram Instagram Discord
Thank You!

No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.